220 related articles for article (PubMed ID: 27678443)
1. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
[TBL] [Abstract][Full Text] [Related]
2. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
de Nijs T; Sniderman A; de Graaf J
Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
[TBL] [Abstract][Full Text] [Related]
3. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
[TBL] [Abstract][Full Text] [Related]
4. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
[TBL] [Abstract][Full Text] [Related]
6. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.
Sniderman AD; Islam S; Yusuf S; McQueen MJ
Atherosclerosis; 2012 Dec; 225(2):444-9. PubMed ID: 23068583
[TBL] [Abstract][Full Text] [Related]
7. Non-HDL C equals apolipoprotein B: except when it does not!
Sniderman A; Williams K; de Graaf J
Curr Opin Lipidol; 2010 Dec; 21(6):518-24. PubMed ID: 20827192
[TBL] [Abstract][Full Text] [Related]
8. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
9. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
[TBL] [Abstract][Full Text] [Related]
10. Assessment of apoB dyslipoproteinemia in Korean population.
Moon HW; Park CM; Hong SN; Park S; Hur M; Yun YM
Clin Biochem; 2013 Aug; 46(12):1041-1046. PubMed ID: 23685223
[TBL] [Abstract][Full Text] [Related]
11. [What is a good marker for serum cholesterol to identify high-risk patients at general health checks?].
Fujioka Y
Rinsho Byori; 2012 Apr; 60(4):328-35. PubMed ID: 22686042
[TBL] [Abstract][Full Text] [Related]
12. Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?
Sniderman AD; Islam S; Yusuf S; McQueen MJ
J Clin Lipidol; 2013; 7(6):626-31. PubMed ID: 24314360
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
Sniderman AD; Williams K; Contois JH; Monroe HM; McQueen MJ; de Graaf J; Furberg CD
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):337-45. PubMed ID: 21487090
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
16. Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness.
Qu G; Zhang Z; Zhu H
Lipids Health Dis; 2021 Jul; 20(1):80. PubMed ID: 34325713
[TBL] [Abstract][Full Text] [Related]
17. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.
Liem AH; van de Woestijne AP; Roeters van Lennep HW; Zwinderman AH; van der Steeg WA; Jukema JW
Curr Med Res Opin; 2008 Feb; 24(2):359-64. PubMed ID: 18081989
[TBL] [Abstract][Full Text] [Related]
18. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study.
Wilkins JT; Li RC; Sniderman A; Chan C; Lloyd-Jones DM
J Am Coll Cardiol; 2016 Jan; 67(2):193-201. PubMed ID: 26791067
[TBL] [Abstract][Full Text] [Related]
19. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
20. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
